Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A prospective cohort analysis.

Zhou L, Peng L

Open source

DOI
10.5937/jomb0-60451
Published
2026 Mar 17
Container
Journal of medical biochemistry
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.5937/jomb0-60451,
  title = {Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A prospective cohort analysis.},
  author = {Zhou L and Peng L},
  year = {2026},
  journal = {Journal of medical biochemistry},
  doi = {10.5937/jomb0-60451},
  url = {https://doi.org/10.5937/jomb0-60451}
}

RIS

TY  - JOUR
TI  - Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A prospective cohort analysis.
AU  - Zhou L
AU  - Peng L
PY  - 2026
JO  - Journal of medical biochemistry
DO  - 10.5937/jomb0-60451
UR  - https://doi.org/10.5937/jomb0-60451
ER  - 

APA

L, Z., & L, P. (2026). Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A prospective cohort analysis.. Journal of medical biochemistry. https://doi.org/10.5937/jomb0-60451

Source records